Overview

A Study of IMM01 Plus Tiselizumab Versus Physician's Choice Chemotherapy in PD(L)1-refractory Classical Hodgkin Lymphoma

Status:
NOT_YET_RECRUITING

Trial end date:
2029-07-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to compare efficacy of IMM01 plus Tiselizumab with physician's choice chemotherapy of bendamustine or gemcitabine in participants with PD-(L)1-refractory classical Hodgkin Lymphoma. The study will also assess the safety and tolerability of IMM01 plus Tiselizumab. The primary study hypotheses are that IMM01 plus Tiselizuma is superior to physician's choice chemotherapy with respect to progression-free survival (PFS) and overall survival (OS).

Phase:

PHASE3

Details

Lead Sponsor:

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Treatments:

Bendamustine Hydrochloride
Gemcitabine
tislelizumab